US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.37

+0.01270.05%

Post-market: 27.500.1304+0.48%16:10 EDT

Volume:1K

Turnover:32.81K

Market Cap:2.46M

PE:- -

High:27.50

Open:27.40

Low:27.37

Close:27.36

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:3.97

T/O Rate:1.33%

Dividend:0.45

Dividend Rate:1.65%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Shenzhen Chipscreen Biosciences Gets China Clinical Trial Approval for Leukemia Tablets

MT Newswires Live

Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances

PharmAla reports Q3 revenue C$513,000 vs. C$135,000 last year

Clearmind Medicine announces safety results from Part A of CMND-100 tral

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

AI Chip Demand Drives Massive 19-Fold Profit Surge for Samsung in Second Quarter

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Capricor Therapeutics announces publication of HOPE-3 data on deramiocel

Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)

Viatris receives FDA approval for Gwyn Lo contraceptive patch

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

NFL Biosciences Streamlines Phase 2 TONIC Trial for Botanical Smoking Cessation Drug NFL-102

Kazia Therapeutics Files Provisional Patent Backing New Paxalisib Strategy in High-Risk Early TNBC

Clearmind Medicine completes Part A of CMND-100 trial

Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184

Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Opening Day: Scribe Therapeutics makes strong trading debut

Freenome, Abbott announce FDA approval of SimpleScreen CRC

Kura Oncology announces durable activity of darlifarnib combination in ccRCC

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/NVIB/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.3696,"timestamp":1789156800000,"preClose":27.3569,"halted":0,"volume":1193,"hourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"delay":0,"changeRate":0.000464233886149338,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.0127,"latestTime":"09-11 16:00:00 EDT","open":27.401,"high":27.5,"low":27.3696,"amount":32812,"amplitude":0.004767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.3569,"nav":27.337,"aum":2460334.39,"dividendRate":0.016467,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"volumeRatio":3.974015203722743},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.974015203722743,"shares":90001,"dividePrice":0.4507,"high":27.5,"amplitude":0.004767,"preClose":27.3569,"low":27.3696,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":27.3696,"eps":0,"divideRate":0.016467,"volume":1193,"delay":0,"ttmEps":0,"open":27.401,"prevYearClose":25,"prevWeekClose":28.8896,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":28.4889,"twentyDayClose":28.3265},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655357622","title":"Shenzhen Chipscreen Biosciences Gets China Clinical Trial Approval for Leukemia Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2655357622","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655357622?lang=en_us&edition=fundamental","pubTime":"2026-07-31 18:19","pubTimestamp":1785493195,"startTime":"0","endTime":"0","summary":"Shenzhen Chipscreen Biosciences  received clinical trial approval from China's National Medical Products Administration for its self-developed CS43158 tablets, according to a Friday filing with the Shanghai Stock Exchange.The drug, approved for domestic clinical trials in China, is indicated for acute myeloid leukemia.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IDNA","NVIB","688321","GDOC","MEDX","HYLG","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655035713","title":"Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2655035713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655035713?lang=en_us&edition=fundamental","pubTime":"2026-07-31 18:12","pubTimestamp":1785492749,"startTime":"0","endTime":"0","summary":"An update from N4 Pharma ( ($GB:THAT) ) is now available. Thalia Therapeutics plc, an AIM-listed clinical-stage biotech specialising in RNA-based t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-updates-voting-rights-as-rna-therapy-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-updates-voting-rights-as-rna-therapy-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","IE0009354923.USD","NVIB","BK4505","XBIX","RNA","BBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655030638","title":"PharmAla reports Q3 revenue C$513,000 vs. C$135,000 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2655030638","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655030638?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:00","pubTimestamp":1785420050,"startTime":"0","endTime":"0","summary":"“PharmAla’s (MDXXF) financial position continues to improve compared to 2025, in line with the broader growth of the biotech industry,” said Nick K...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pharmala-reports-q3-revenue-c513000-vs-c135000-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pharmala-reports-q3-revenue-c513000-vs-c135000-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDXXF","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655803050","title":"Clearmind Medicine announces safety results from Part A of CMND-100 tral","url":"https://stock-news.laohu8.com/highlight/detail?id=2655803050","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655803050?lang=en_us&edition=fundamental","pubTime":"2026-07-30 21:45","pubTimestamp":1785419153,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced safety results from Part A of its ongoing FDA-regulated Phase I/II clinical trial evaluating CMND-100, the comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-safety-results-from-part-a-of-cmnd-100-tral-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-safety-results-from-part-a-of-cmnd-100-tral-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NVIB","LABU","CMND","IDNA","BK4588","MEDX","HYLG","BK4585","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655808400","title":"Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2655808400","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655808400?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:30","pubTimestamp":1785414600,"startTime":"0","endTime":"0","summary":"REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3336054/0/en/Newly-FDA-Approved-REVTORPYK-gedatolisib-Included-in-the-National-Comprehensive-Cancer-Network-NCCN-Clinical-Practice-Guidelines-for-HR-HER2-Locally-Advanced-or-Metastatic-Breast-C.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","BK4157","NVIB","IE00B7SZL793.SGD","BK4225","SRET","LU0757428866.USD","IE0031619046.USD","LABU","IE00B66KJ199.SGD","NHLD","HYLG","BK4599","BK4588","GDOC","IDNA","LU1815336091.USD","BK4139","HR","AEIS","ALT","IE00B19Z4B17.USD","LU1878469433.USD","BK4203","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145548677","title":"AI Chip Demand Drives Massive 19-Fold Profit Surge for Samsung in Second Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=1145548677","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145548677?lang=en_us&edition=fundamental","pubTime":"2026-07-30 08:12","pubTimestamp":1785370320,"startTime":"0","endTime":"0","summary":"Samsung Electronics reported on Thursday that its second-quarter operating profit surged by an extraordinary 19 times, reaching a new record high. This performance was fueled by robust demand for...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MULL","AMAU","BK4585","MUD","INTW","MUYY","NVIB","MUZ","EMXC","MUU","MIC","LINT","PSAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655811687","title":"Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2655811687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655811687?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:30","pubTimestamp":1785357000,"startTime":"0","endTime":"0","summary":"- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335623/0/en/Dyne-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNS","GDOC","BK4588","BMED","DYN","LABU","NVIB","IND","BK4505","IDNA","REC","MEDX","BK4135","HYLG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655899327","title":"Capricor Therapeutics announces publication of HOPE-3 data on deramiocel","url":"https://stock-news.laohu8.com/highlight/detail?id=2655899327","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655899327?lang=en_us&edition=fundamental","pubTime":"2026-07-29 22:10","pubTimestamp":1785334232,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics (CAPR) announced that The Lancet has published results from the Company’s pivotal Phase 3 HOPE-3 clinical trial evaluating De...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/capricor-therapeutics-announces-publication-of-hope-3-data-on-deramiocel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/capricor-therapeutics-announces-publication-of-hope-3-data-on-deramiocel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4139","HOPE","CAPR","IDNA","MEDX","GDOC","HYLG","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655895299","title":"Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655895299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655895299?lang=en_us&edition=fundamental","pubTime":"2026-07-29 21:30","pubTimestamp":1785331817,"startTime":"0","endTime":"0","summary":"WSW, NY, July 29th, 2026, FinanceWire Silexion Therapeutics (NASDAQ:SLXN) just announced that it initiated its Phase 2/3 clinical trial of SIL204 a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQY","TQQQ","PSQ","GPIQ","MEDX","QYLG","NDX","BK4139","JEPQ","QQQM","SQQQ","QID","QQQE","MNQmain","ONEQ","QQQA","TECS","QQQ","NQmain","GDOC","IDNA","NVIB","NVIW.SI","SLXN",".IXIC","QDTE","IYW","QLD","HYLG","FTEC","QQQJ","TQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655895830","title":"Viatris receives FDA approval for Gwyn Lo contraceptive patch","url":"https://stock-news.laohu8.com/highlight/detail?id=2655895830","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655895830?lang=en_us&edition=fundamental","pubTime":"2026-07-29 21:16","pubTimestamp":1785330964,"startTime":"0","endTime":"0","summary":"Viatris (VTRS) announced that the FDA has approved Gwyn Lo, a new combined hormonal contraceptive patch with low-dose estrogen. The patch has demon...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/viatris-receives-fda-approval-for-gwyn-lo-contraceptive-patch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/viatris-receives-fda-approval-for-gwyn-lo-contraceptive-patch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","TECB","BK4588","BK4583","FRTY","SYNB","GDOC","MEDI","NVIB","LU1839511570.USD","LU2087621335.USD","BBP","RSPH","GNMX","TBXU","IDNA","BMED","IBB","MRNX","IEIH","IYH","LFSC","BK4585","VTRS","PSCH","MRNY","XLVX","PINK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655089689","title":"RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2655089689","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655089689?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:30","pubTimestamp":1785328200,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., July  29, 2026  (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335203/0/en/RenovoRx-to-Host-Second-Quarter-2026-Financial-Results-and-Business-Highlights-Conference-Call-on-August-12th-at-4-30-p-m-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENFR","HST","MEDX","AMLP","BK4181","BK4218","BK4581","BK4539","GDOC","TNGY","USAI","HYLG","BK4585","BMED","BK4139","BK4590","BK4561","IDNA","BK4588","MLPA","EIPI","ET","EMLP","LABU","BK4144","MDST","EIPX","AMZA","NVIB","UMI","RNXT","TPZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655886025","title":"NFL Biosciences Streamlines Phase 2 TONIC Trial for Botanical Smoking Cessation Drug NFL-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2655886025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655886025?lang=en_us&edition=fundamental","pubTime":"2026-07-29 00:17","pubTimestamp":1785255458,"startTime":"0","endTime":"0","summary":"An announcement from NFL Biosciences SA ( ($FR:ALNFL) ) is now available. NFL Biosciences has submitted its TONIC Phase 2 clinical trial protocol t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nfl-biosciences-streamlines-phase-2-tonic-trial-for-botanical-smoking-cessation-drug-nfl-102?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nfl-biosciences-streamlines-phase-2-tonic-trial-for-botanical-smoking-cessation-drug-nfl-102?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","HYLG","IDNA","MEDX","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001714","title":"Kazia Therapeutics Files Provisional Patent Backing New Paxalisib Strategy in High-Risk Early TNBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001714?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:57","pubTimestamp":1785239835,"startTime":"0","endTime":"0","summary":"An update from Kazia Therapeutics ( ($KZIA) ) is now available. Kazia Therapeutics Limited, a Sydney-based oncology biotech listed on Nasdaq, is de...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-files-provisional-patent-backing-new-paxalisib-strategy-in-high-risk-early-tnbc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-files-provisional-patent-backing-new-paxalisib-strategy-in-high-risk-early-tnbc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LCLG","LENZ","XBIX","CANC","BK4539","NQmain","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001793","title":"Clearmind Medicine completes Part A of CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001793","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001793?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:55","pubTimestamp":1785239759,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced the completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-completes-part-a-of-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-completes-part-a-of-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4007","GDOC","CMND","NVIB","IDNA","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001704","title":"Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001704","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001704?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:50","pubTimestamp":1785239443,"startTime":"0","endTime":"0","summary":"Lantern Pharma (LTRN) announced that an investigator-initiated Phase 1b/2 clinical trial of its lead drug candidate LP-184 in advanced, recurrent b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lantern-pharma-to-advance-ema-cleared-phase-1b-2-trial-of-lp-184-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lantern-pharma-to-advance-ema-cleared-phase-1b-2-trial-of-lp-184-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4081","LTRN","BK4139","EMA","GDOC","IDNA","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009072","title":"Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009072","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009072?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:40","pubTimestamp":1785238813,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics (DYN) announced that it has received clearance from the FDA for its IND application to initiate a Phase 1 clinical trial for DYNE...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dyne-therapeutics-receives-fda-clearance-to-initiate-dyne-302-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dyne-therapeutics-receives-fda-clearance-to-initiate-dyne-302-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","IND","LABU","BK4585","BK4139","BK4134","DYN","DYNE","BK4588","BK4505","HYLG","GDOC","IDNA","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654043980","title":"Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution","url":"https://stock-news.laohu8.com/highlight/detail?id=2654043980","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654043980?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:30","pubTimestamp":1785238200,"startTime":"0","endTime":"0","summary":"– ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –– KPL-387","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334131/0/en/Kiniksa-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Portfolio-Execution.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","IDNA","BK4104","RW","BK4139","MEDX","GDOC","CAPS","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654730049","title":"Opening Day: Scribe Therapeutics makes strong trading debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2654730049","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654730049?lang=en_us&edition=fundamental","pubTime":"2026-07-27 23:25","pubTimestamp":1785165946,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the mar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opening-day-scribe-therapeutics-makes-strong-trading-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opening-day-scribe-therapeutics-makes-strong-trading-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","LU1861558580.USD","SCTX","NVIB","XBIX","BK4556","BK4588","IPOS","BK4139","BK4611","LU1861559042.SGD","ARKG","CRSP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654010379","title":"Freenome, Abbott announce FDA approval of SimpleScreen CRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010379","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654010379?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:16","pubTimestamp":1785154580,"startTime":"0","endTime":"0","summary":"Freenome (FRNM) and Abbott (ABT) announced that the FDA has approved SimpleScreen CRC, a new blood-based screening option for colorectal cancer in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/freenome-abbott-announce-fda-approval-of-simplescreen-crc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/freenome-abbott-announce-fda-approval-of-simplescreen-crc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","MEDI","TBXU","LU2468319806.SGD","IDNA","BK4588","GDOC","LU2112291526.USD","LU1061106388.HKD","LU1914381329.SGD","BK4504","BK4082","LU0266013472.USD","NVIB","PINK","TECB","BK4585","IE0002141913.USD","SGXZ41872573.SGD","XLVX","LU1721429741.USD","PJP","MRNY","SG9999002232.USD","PSCH","IYH","GNMX","CRC","LU2324357040.USD","IBB","IHI","LU0868494617.USD","LU0170899867.USD","SYNB","LU0266512127.USD","MRNX","LFSC","TMED","LU1691799644.USD","FRNM","FRTY","SG9999002224.SGD","BK4213","RSPH","LU1721429402.USD","BMED","LABU","ABT","IEIH","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654011607","title":"Kura Oncology announces durable activity of darlifarnib combination in ccRCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2654011607","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654011607?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:40","pubTimestamp":1785148845,"startTime":"0","endTime":"0","summary":"Kura Oncology (KURA) announced updated Phase 1a results from the ongoing FIT-001 clinical trial demonstrating encouraging and durable clinical acti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kura-oncology-announces-durable-activity-of-darlifarnib-combination-in-ccrcc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kura-oncology-announces-durable-activity-of-darlifarnib-combination-in-ccrcc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","MEDX","NVIB","HYLG","GDOC","KURA","IDNA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":8,"totalSize":170,"code":"91000000","status":"200"}]}}